A New Paradigm for Precision Drug Delivery in Inflammatory Bowel Disease: Effective Transfer, Enhanced Retention, and Pathology-Targeting Treatment via Biomaterials and Engineered Platforms

Abstract

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the gastrointestinal (GI) tract with increasing global prevalence. Despite advancements in IBD management, current therapies suffer from limitations, such as premature drug degradation, insufficient retention at inflamed sites, and systemic off-target effects, resulting in suboptimal efficacy and increased adverse events. To address these challenges, this review presents a new paradigm for precision drug delivery in IBD, highlighting three critical strategies: (1) effective transfer—ensuring efficient drug transport to the intestinal region by overcoming complex GI physiological barriers; (2) enhanced retention—prolonging drug residence at inflamed lesions to maximize local therapeutic effects; and (3) pathology-targeting treatment—executing therapeutic interventions based on IBD-associated pathological features to achieve localized treatment and minimize systemic toxicity. We emphasize the integration of advanced biomaterials and engineered therapeutic platforms as enablers of these strategies and illustrate their interactions with IBD pathophysiology. By analyzing recent breakthroughs in drug delivery systems and bioresponsive materials, this review outlines the design principles and translational potential of next-generation IBD therapeutics, offering insights for the development of more effective and patient-centric treatment approaches.

Keywords

biomaterials / drug delivery systems / inflammatory bowel disease (IBD) / multidisciplinary engineering / precision medicine

References

[1] R. Ungaro, S. Mehandru, P. B. Allen, L. Peyrin-Biroulet, and J. F. Colombel, “Ulcerative Colitis,” Lancet 389, no. 10080 (2017): 1756–1770.

[2] G. Roda, S. Chien Ng, P. G. Kotze, et al., “Crohn's Disease,” Nature Reviews Disease Primers 6, no. 1 (2020): 22.

[3] G. G. Kaplan, “The Global Burden of IBD: From 2015 to 2025,” Nature Reviews Gastroenterology & Hepatology 12, no. 12 (2015): 720–727.

[4] S. C. Ng, H. Y. Shi, N. Hamidi, et al., “Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies,” Lancet 390, no. 10114 (2017): 2769–2778.

[5] N. A. Molodecky, I. S. Soon, D. M. Rabi, et al., “Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review,” Gastroenterology 142, no. 1 (2012): 46–54.e42.

[6] B. Khor, A. Gardet, and R. J. Xavier, “Genetics and Pathogenesis of Inflammatory Bowel Disease,” Nature 474, no. 7351 (2011): 307–317.

[7] R. J. Xavier and D. K. Podolsky, “Unravelling the Pathogenesis of Inflammatory Bowel Disease,” Nature 448, no. 7152 (2007): 427–434.

[8] E. V. Loftus, , “Clinical Epidemiology of Inflammatory Bowel Disease: Incidence, Prevalence, and Environmental Influences,” Gastroenterology 126, no. 6 (2004): 1504–1517.

[9] A. N. Ananthakrishnan, C. N. Bernstein, D. Iliopoulos, et al., “Environmental Triggers in IBD: A Review of Progress and Evidence,” Nature Reviews Gastroenterology & Hepatology 15, no. 1 (2018): 39–49.

[10] Y. Shan, M. Lee, and E. B. Chang, “The Gut Microbiome and Inflammatory Bowel Diseases,” Annual Review of Medicine 73 (2022): 455–468.

[11] H. S. P. de Souza and C. Fiocchi, “Immunopathogenesis of IBD: Current State of the Art,” Nature Reviews Gastroenterology & Hepatology 13, no. 1 (2016): 13–27.

[12] J. T. Chang, “Pathophysiology of Inflammatory Bowel Diseases,” New England Journal of Medicine 383, no. 27 (2020): 2652–2664.

[13] M. L. Hoivik, B. Moum, I. C. Solberg, et al., “Health-Related Quality of Life in Patients With Ulcerative Colitis After a 10-Year Disease Course: Results From the Ibsen Study,” Inflammatory Bowel Diseases 18, no. 8 (2012): 1540–1549.

[14] G. Rogler, A. Singh, A. Kavanaugh, and D. T. Rubin, “Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management,” Gastroenterology 161, no. 4 (2021): 1118–1132.

[15] S. C. Shah and S. H. Itzkowitz, “Colorectal Cancer in Inflammatory Bowel Disease: Mechanisms and Management,” Gastroenterology 162, no. 3 (2022): 715–730.e3.

[16] S. Massironi, C. Viganò, A. Palermo, et al., “Inflammation and Malnutrition in Inflammatory Bowel Disease,” Lancet Gastroenterology & Hepatology 8, no. 6 (2023): 579–590.

[17] C. Le Berre, A. Ricciuto, L. Peyrin-Biroulet, and D. Turner, “Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last,” Gastroenterology 162, no. 5 (2022): 1424–1438.

[18] A. R. Weingarden and B. P. Vaughn, “Intestinal Microbiota, Fecal Microbiota Transplantation, and Inflammatory Bowel Disease,” Gut Microbes 8, no. 3 (2017): 238–252.

[19] D. C. Baumgart and C. Le Berre, “Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease,” New England Journal of Medicine 385, no. 14 (2021): 1302–1315.

[20] K. B. Gecse and P. L. Lakatos, “Biologicals and Biosimilars in IBD — The Road to Personalized Treatment,” Nature Reviews Gastroenterology & Hepatology 14, no. 2 (2017): 74–76.

[21] G. R. Gandhi, T. Mohana, K. Athesh, et al., “Anti-Inflammatory Natural Products Modulate Interleukins and Their Related Signaling Markers in Inflammatory Bowel Disease: A Systematic Review,” Journal of Pharmaceutical Analysis 13, no. 12 (2023): 1408–1428.

[22] J. Liu, B. Di, and L. Xu, “Recent Advances in the Treatment of IBD: Targets, Mechanisms and Related Therapies,” Cytokine & Growth Factor Reviews 71–72 (2023): 1–12.

[23] D. García-Olmo, M. García-Arranz, L. G. García, et al., “Autologous Stem Cell Transplantation for Treatment of Rectovaginal Fistula in Perianal Crohn's Disease: A New Cell-Based Therapy,” International Journal of Colorectal Disease 18, no. 5 (2003): 451–454.

[24] J. Panés, D. García-Olmo, G. Van Assche, et al., “Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells (Cx601) for Complex Perianal Fistulas in Crohn's Disease: A Phase 3 Randomised, Double-Blind Controlled Trial,” Lancet 388, no. 10051 (2016): 1281–1290.

[25] zM. F. Neurath, “Strategies for Targeting Cytokines in Inflammatory Bowel Disease,” Nature Reviews Immunology 24, no. 8 (2024): 559–576.

[26] H. Yanai and S. B. Hanauer, “Assessing Response and Loss of Response to Biological Therapies in IBD,” American Journal of Gastroenterology 106, no. 4 (2011): 685–698.

[27] J. S. Davis, D. Ferreira, E. Paige, C. Gedye, and M. Boyle, “Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies,” Clinical Microbiology Reviews 33, no. 3 (2020): e00035-00019.

[28] S. Bots, K. Gecse, M. Barclay, and G. D'Haens, “Combination Immunosuppression in IBD,” Inflammatory Bowel Diseases 24, no. 3 (2018): 539–545.

[29] K. Papamichael, W. Afif, D. Drobne, et al., “Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease: Unmet Needs and Future Perspectives,” Lancet Gastroenterology & Hepatology 7, no. 2 (2022): 171–185.

[30] T. Pérez-Jeldres, M. Alvarez-Lobos, and J. Rivera-Nieves, “Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis,” Drugs 81, no. 9 (2021): 985–1002.

[31] M. Lee and E. B. Chang, “Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues,” Gastroenterology 160, no. 2 (2021): 524–537.

[32] K. L. Glassner, B. P. Abraham, and E. M. M. Quigley, “The Microbiome and Inflammatory Bowel Disease,” Journal of Allergy and Clinical Immunology 145, no. 1 (2020): 16–27.

[33] C. M. Tian, Y. Zhang, M. F. Yang, et al., “Stem Cell Therapy in Inflammatory Bowel Disease: A Review of Achievements and Challenges,” Journal of Inflammation Research 16 (2023): 2089–2119.

[34] H. M. Zhang, S. Yuan, H. Meng, et al., “Stem Cell-Based Therapies for Inflammatory Bowel Disease,” International Journal of Molecular Sciences 23, no. 15 (2022): 8494.

[35] L. Thangavelu, S. Mohan, H. A. Alfaifi, et al., “Safety and Efficacy of Stem Cell Therapy for Crohn's Disease: An Umbrella Review of Systematic Reviews,” International Journal of Surgery 110, no. 12 (2024): 7495–7507.

[36] F. Rieder, E. M. Zimmermann, F. H. Remzi, and W. J. Sandborn, “Crohn's Disease Complicated by Strictures: A Systematic Review,” Gut 62, no. 7 (2013): 1072–1084.

[37] F. Rieder, C. Fiocchi, and G. Rogler, “Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases,” Gastroenterology 152, no. 2 (2017): 340–350.e6.

[38] K. Cushing and P. D. R. Higgins, “Management of Crohn Disease: A Review,” Journal of the American Medical Association 325, no. 1 (2021): 69–80.

[39] D. W. Larson and J. H. Pemberton, “Current Concepts and Controversies in Surgery for IBD,” Gastroenterology 126, no. 6 (2004): 1611–1619.

[40] V. Annese, D. Duricova, C. Gower-Rousseau, T. Jess, and E. Langholz, “Impact of New Treatments on Hospitalisation, Surgery, Infection, and Mortality in IBD: A Focus Paper by the Epidemiology Committee of ECCO,” Journal of Crohn's and Colitis 10, no. 2 (2016): 216–225.

[41] L. E. McCoubrey, A. Favaron, A. Awad, M. Orlu, S. Gaisford, and A. W. Basit, “Colonic Drug Delivery: Formulating the Next Generation of Colon-Targeted Therapeutics,” Journal of Controlled Release 353 (2023): 1107–1126.

[42] M. Dhyani, N. Joshi, W. A. Bemelman, et al., “Challenges in IBD Research: Novel Technologies,” Inflammatory Bowel Diseases 25, no. Suppl 2 (2019): S24–S30.

[43] S. Prasad, R. K. Cross, M. B. Monroe, et al., “Challenges in IBD Research 2024: Novel Technologies,” Inflammatory Bowel Diseases 30, no. Suppl_2 (2024): S30–S38.

[44] J. N. Chu and G. Traverso, “Foundations of Gastrointestinal-Based Drug Delivery and Future Developments,” Nature Reviews Gastroenterology & Hepatology 19, no. 4 (2022): 219–238.

[45] R. Kumar, T. Islam, and M. Nurunnabi, “Mucoadhesive Carriers for Oral Drug Delivery,” Journal of Controlled Release 351 (2022): 504–559.

[46] C. Günther, H. Neumann, M. F. Neurath, and C. Becker, “Apoptosis, Necrosis and Necroptosis: Cell Death Regulation in the Intestinal Epithelium,” Gut 62, no. 7 (2013): 1062–1071.

[47] B. Gros and G. G. Kaplan, “Ulcerative Colitis in Adults: A Review,” Journal of the American Medical Association 330, no. 10 (2023): 951–965.

[48] B. Ying, H. Huang, Y. Su, J. G. Howarth, Z. Gu, and K. Nan, “Theranostic Gastrointestinal Residence Systems,” Device 1, no. 2 (2023): 100053.

[49] R. P. Hirten, M. Iacucci, S. Shah, S. Ghosh, and J. F. Colombel, “Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders,” Clinical Gastroenterology and Hepatology 16, no. 9 (2018): 1374–1384.

[50] L. Lichtenstein, Y. Ron, S. Kivity, et al., “Infliximab-Related Infusion Reactions: Systematic Review,” Journal of Crohn's and Colitis 9, no. 9 (2015): 806–815.

[51] C. Jori, A. A. Chaudhary, S. Rashid, et al., “Biomaterial-Based Strategies for Immunomodulation in IBD: Current and Future Scenarios,” Journal of Materials Chemistry B 11, no. 25 (2023): 5668–5692.

[52] W. Sun, Z. Li, X. Zhang, Q. Luo, L. Wei, and C. Xiao, “Biomaterial-Based Therapeutic Strategies for Inflammatory Bowel Disease,” Biomaterials 324 (2026): 123462.

[53] X. Zhang, G. Chen, H. Zhang, L. Shang, and Y. Zhao, “Bioinspired Oral Delivery Devices,” Nature Reviews Bioengineering 1, no. 3 (2023): 208–225.

[54] J. Byrne, H.-W. Huang, J. C. McRae, et al., “Devices for Drug Delivery in the Gastrointestinal Tract: A Review of Systems Physically Interacting With the Mucosa for Enhanced Delivery,” Advanced Drug Delivery Reviews 177 (2021): 113926.

[55] J. Kim and O. De Jesus, “ Medication Routes of Administration.” Statpearls. StatPearls Publishing Copyright © 2025 (StatPearls Publishing LLC, 2025).

[56] D. Gupta, S. V. Gupta, and N. Yang, “ Understanding the Routes of Administration.” in Handbook of Space Pharmaceuticals, eds. Y. V. Pathak, M. Araújo dos Santos, and L. Zea. (Springer International Publishing, 2022), 23–47.

[57] K. K. Jain, “An Overview of Drug Delivery Systems,” Methods in Molecular Biology 2059 (2020): 1–54.

[58] D. Tiwari and N. Batra, “Oral Drug Delivery System: A Review,” International Journal of Advances in Engineering and Management (IJAEM) 2 (2014): 27–35.

[59] R. Rathi, I. Sanshita, A. Kumar, et al., “Advancements in Rectal Drug Delivery Systems: Clinical Trials, and Patents Perspective,” Pharmaceutics 14, no. 10 (2022): 2210.

[60] M. Misbah Ul Haq, M. Razzak, M. A. Uddin, N. Ahmed, and D. Shahidulla, “Rectal Drug Delivery System: An Overview,” Clinical Pharmacology and Biopharmaceutics 10, no. 5 (2021): 1000219.

[61] B. Bittner, W. Richter, and J. Schmidt, “Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities,” BioDrugs 32, no. 5 (2018): 425–440.

[62] I. Usach, R. Martinez, T. Festini, and J.-E. Peris, “Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site,” Advances in Therapy 36, no. 11 (2019): 2986–2996.

[63] U. Klotz and M. Schwab, “Topical Delivery of Therapeutic Agents in the Treatment of Inflammatory Bowel Disease,” Advanced Drug Delivery Reviews 57, no. 2 (2005): 267–279.

[64] C. Lautenschläger, C. Schmidt, D. Fischer, and A. Stallmach, “Drug Delivery Strategies in the Therapy of Inflammatory Bowel Disease,” Advanced Drug Delivery Reviews 71 (2014): 58–76.

[65] R. Arévalo-Pérez, C. Maderuelo, and J. M. Lanao, “Recent Advances in Colon Drug Delivery Systems,” Journal of Controlled Release 327 (2020): 703–724.

[66] S. Hu, R. Zhao, Y. Xu, Z. Gu, B. Zhu, and J. Hu, “Orally-Administered Nanomedicine Systems Targeting Colon Inflammation for the Treatment of Inflammatory Bowel Disease: Latest Advances,” Journal of Materials Chemistry B 12, no. 1 (2023): 13–38.

[67] N. G. Kotla, S. Rana, G. Sivaraman, et al., “Bioresponsive Drug Delivery Systems in Intestinal Inflammation: State-of-the-Art and Future Perspectives,” Advanced Drug Delivery Reviews 146 (2019): 248–266.

[68] A. Ren, J. Hu, C. Qin, et al., “Oral Administration Microrobots for Drug Delivery,” Bioactive Materials 39 (2024): 163–190.

[69] L. Yang, J. S. Chu, and J. A. Fix, “Colon-Specific Drug Delivery: New Approaches and In Vitro/In Vivo Evaluation,” International Journal of Pharmaceutics 235, no. 1–2 (2002): 1–15.

[70] F. Yasmin, H. Najeeb, S. Shaikh, et al., “Novel Drug Delivery Systems for Inflammatory Bowel Disease,” World Journal of Gastroenterology 28, no. 18 (2022): 1922–1933.

[71] T. Yoshida, T. C. Lai, G. S. Kwon, and K. Sako, “pH- and Ion-Sensitive Polymers for Drug Delivery,” Expert Opinion on Drug Delivery 10, no. 11 (2013): 1497–1513.

[72] H. Ding, P. Tan, S. Fu, et al., “Preparation and Application of pH-Responsive Drug Delivery Systems,” Journal of Controlled Release 348 (2022): 206–238.

[73] S. M. Faber and B. I. Korelitz, “Experience With Eudragit-S-Coated Mesalamine (Asacol) in Inflammatory Bowel Disease. An Open Study,” Journal of Clinical Gastroenterology 17, no. 3 (1993): 213–218.

[74] S. Edsb??cker and T. Andersson, “Pharmacokinetics of Budesonide (Entocort EC) Capsules for Crohn's Disease,” Clinical Pharmacokinetics 43, no. 12 (2004): 803–821.

[75] J. M. Wong and S. C. Wei, “Efficacy of Pentasa Tablets for the Treatment of Inflammatory Bowel Disease,” Journal of the Formosan Medical Association = Taiwan yi zhi 102, no. 9 (2003): 613–619.

[76] A. Gazzaniga, A. Maroni, M. E. Sangalli, and L. Zema, “Time-Controlled Oral Delivery Systems for Colon Targeting,” Expert Opinion on Drug Delivery 3, no. 5 (2006): 583–597.

[77] G. S. Macleod, J. T. Fell, J. H. Collett, H. L. Sharma, and A. M. Smith, “Selective Drug Delivery to the Colon Using Pectin:Chitosan:Hydroxypropyl Methylcellulose Film Coated Tablets,” International Journal of Pharmaceutics 187, no. 2 (1999): 251–257.

[78] G. Van den Mooter, B. Maris, C. Samyn, P. Augustijns, and R. Kinget, “Use of Azo Polymers for Colon-Specific Drug Delivery,” Journal of Pharmaceutical Sciences 86, no. 12 (1997): 1321–1327.

[79] M. K. Chourasia and S. K. Jain, “Polysaccharides for Colon Targeted Drug Delivery,” Drug Delivery 11, no. 2 (2004): 129–148.

[80] A. Swidsinski, A. Ladhoff, A. Pernthaler, et al., “Mucosal Flora in Inflammatory Bowel Disease,” Gastroenterology 122, no. 1 (2002): 44–54.

[81] T. Takaya, K. Sawada, H. Suzuki, A. Funaoka, K. I. Matsuda, and K. Takada, “Application of a Colon Delivery Capsule to 5-Aminosalicylic Acid and Evaluation of the Pharmacokinetic Profile After Oral Administration to Beagle Dogs,” Journal of Drug Targeting 4, no. 5 (1997): 271–276.

[82] Y. I. Jeong, T. Ohno, Z. Hu, et al., “Evaluation of an Intestinal Pressure-Controlled Colon Delivery Capsules Prepared by a Dipping Method,” Journal of Controlled Release 71, no. 2 (2001): 175–182.

[83] F. Abdi, M. G. Buzhor, N. Zellweger, L. Zhi-Luo, and J. C. Leroux, “pH-Dependent Pressure-Sensitive Colonic Capsules for the Delivery of Aqueous Bacterial Suspensions,” Journal of Controlled Release 365 (2024): 688–702.

[84] A. Awad, C. M. Madla, L. E. McCoubrey, et al., “Clinical Translation of Advanced Colonic Drug Delivery Technologies,” Advanced Drug Delivery Reviews 181 (2022): 114076.

[85] L. F. Sun, M. M. Li, Y. Chen, et al., “pH/Enzyme Dual Sensitive Gegenqinlian Pellets Coated With Bletilla striata Polysaccharide Membranes for the Treatment of Ulcerative Colitis,” Colloids and Surfaces B: Biointerfaces 229 (2023): 113453.

[86] M. Zeeshan, Q. U. Ain, B. Weigmann, D. Story, B. R. Smith, and H. Ali, “Dual pH and Microbial-Sensitive Galactosylated Polymeric Nanocargoes for Multi-Level Targeting to Combat Ulcerative Colitis,” Asian Journal of Pharmaceutical Sciences 18, no. 4 (2023): 100831.

[87] Y. Wang, X. Song, R. Cui, et al., “Dual-Sensitive Carbohydrate-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis,” International Journal of Nanomedicine 19 (2024): 8555–8572.

[88] R. Luo, J. Liu, Q. Cheng, M. Shionoya, C. Gao, and R. Wang, “Oral Microsphere Formulation of M2 Macrophage-Mimetic Janus Nanomotor for Targeted Therapy of Ulcerative Colitis,” Science Advances 10, no. 26 (2024): eado6798.

[89] H. Liu, Z. Cai, F. Wang, et al., “Colon-Targeted Adhesive Hydrogel Microsphere for Regulation of Gut Immunity and Flora,” Advanced Science 8, no. 18 (2021): 2101619.

[90] H. He, Q. Qin, F. Xu, et al., “Oral Polyphenol-Armored Nanomedicine for Targeted Modulation of Gut Microbiota-Brain Interactions in Colitis,” Science Advances 9, no. 21 (2023): eadf3887.

[91] L. Zhu, T. Yu, W. Wang, et al., “Responsively Degradable Nanoarmor-Assisted Super Resistance and Stable Colonization of Probiotics for Enhanced Inflammation-Targeted Delivery,” Advanced Materials 36, no. 18 (2024): e2308728.

[92] Y. Liu, J. Huang, S. Li, et al., “Advancements in Hydrogel-Based Drug Delivery Systems for the Treatment of Inflammatory Bowel Disease: A Review,” Biomaterials Science 12, no. 4 (2024): 837–862.

[93] J. Liu, H. Ren, C. Zhang, et al., “Orally-Delivered, Cytokine-Engineered Extracellular Vesicles for Targeted Treatment of Inflammatory Bowel Disease,” Small 19, no. 50 (2023): e2304023.

[94] C. Ren, D. Zhong, Y. Qi, et al., “Bioinspired pH-Responsive Microalgal Hydrogels for Oral Insulin Delivery With Both Hypoglycemic and Insulin Sensitizing Effects,” ACS Nano 17, no. 14 (2023): 14161–14175.

[95] W.-C. Huang, W. Wang, W. Wang, Y. Hao, C. Xue, and X. Mao, “A Double-Layer Polysaccharide Hydrogel (DPH) for the Enhanced Intestine-Targeted Oral Delivery of Probiotics,” Engineering 34 (2024): 187–194.

[96] S. Liang, D. Zhao, X. Liu, B. Liu, and Y. Li, “The Stomach, Small Intestine, and Colon-Specific Gastrointestinal Tract Delivery Systems for Bioactive Nutrients,” Advances in Colloid and Interface Science 341 (2025): 103503.

[97] D. Wang, Q. Jiang, Z. Dong, et al., “Nanocarriers Transport Across the Gastrointestinal Barriers: The Contribution to Oral Bioavailability via Blood Circulation and Lymphatic Pathway,” Advanced Drug Delivery Reviews 203 (2023): 115130.

[98] W. Li, Y. Li, Z. Liu, et al., “Hierarchical Structured and Programmed Vehicles Deliver Drugs Locally to Inflamed Sites of Intestine,” Biomaterials 185 (2018): 322–332.

[99] D. Li, M. Yang, H. Xu, et al., “Nanoparticles for Oral Delivery: Targeted Therapy for Inflammatory Bowel Disease,” Journal of Materials Chemistry B 10, no. 31 (2022): 5853–5872.

[100] Z. Liu, H. Liu, J. Cheng, et al., “Strategies and Opportunities of Micro/Nano Delivery Systems for Targeted Therapy of Ulcerative Colitis: Focus on Underlying Mechanisms and Future Perspectives,” Chinese Chemical Letters 35, no. 2 (2024): 109074.

[101] M. Abid, M. Naveed, I. Azeem, A. Faisal, M. Faizan Nazar, and B. Yameen, “Colon Specific Enzyme Responsive Oligoester Crosslinked Dextran Nanoparticles for Controlled Release of 5-Fluorouracil,” International Journal of Pharmaceutics 586 (2020): 119605.

[102] Y. Wang, J. Shen, S. Handschuh-Wang, M. Qiu, S. Du, and B. Wang, “Microrobots for Targeted Delivery and Therapy in Digestive System,” ACS Nano 17, no. 1 (2023): 27–50.

[103] Y. Liu, G. Lin, M. Medina-Sánchez, M. Guix, D. Makarov, and D. Jin, “Responsive Magnetic Nanocomposites for Intelligent Shape-Morphing Microrobots,” ACS Nano 17, no. 10 (2023): 8899–8917.

[104] Y. Kim and X. Zhao, “Magnetic Soft Materials and Robots,” Chemical Reviews 122, no. 5 (2022): 5317–5364.

[105] M. Koleoso, X. Feng, Y. Xue, Q. Li, T. Munshi, and X. Chen, “Micro/Nanoscale Magnetic Robots for Biomedical Applications,” Materials Today Bio 8 (2020): 100085.

[106] Z. Ren and M. Sitti, “Design and Build of Small-Scale Magnetic Soft-Bodied Robots With Multimodal Locomotion,” Nature Protocols 19, no. 2 (2024): 441–486.

[107] P. Swain, A. Toor, F. Volke, et al., “Remote Magnetic Manipulation of a Wireless Capsule Endoscope in the Esophagus and Stomach of Humans (With),” Gastrointestinal Endoscopy 71, no. 7 (2010): 1290–1293.

[108] Z. Wang, Q. Li, P. Cao, et al., “A Biomimetic Helical Robot Actuated by Rotating Magnetic Field for Targeted Navigation and In Situ Prodrug Activation to Treat Intestinal Diseases,” Device 1, no. 3 (2023): 100064.

[109] X. Zhang, G. Chen, X. Fu, Y. Wang, and Y. Zhao, “Magneto-Responsive Microneedle Robots for Intestinal Macromolecule Delivery,” Advanced Materials 33, no. 44 (2021): e2104932.

[110] R. H. Soon, Z. Yin, M. A. Dogan, et al., “Pangolin-Inspired Untethered Magnetic Robot for On-Demand Biomedical Heating Applications,” Nature Communications 14, no. 1 (2023): 3320.

[111] K. Liu, Q. Liu, J. Yang, et al., “Micromotor Based Mini-Tablet for Oral Delivery of Insulin,” ACS Nano 17, no. 1 (2023): 300–311.

[112] G. Arrick, D. Sticker, A. Ghazal, et al., “Cephalopod-Inspired Jetting Devices for Gastrointestinal Drug Delivery,” Nature 636, no. 8042 (2024): 481–487.

[113] D. Zhong, D. Zhang, W. Chen, et al., “Orally Deliverable Strategy Based on Microalgal Biomass for Intestinal Disease Treatment,” Science Advances 7, no. 48 (2021): eabi9265.

[114] Z. Li, Y. Duan, F. Zhang, et al., “Biohybrid Microrobots Regulate Colonic Cytokines and the Epithelium Barrier in Inflammatory Bowel Disease,” Science Robotics 9, no. 91 (2024): eadl2007.

[115] Y. Sun, W. Zhang, J. Gu, et al., “Magnetically Driven Capsules With Multimodal Response and Multifunctionality for Biomedical Applications,” Nature Communications 15, no. 1 (2024): 1839.

[116] H. Han, X. Ma, W. Deng, et al., “Imaging-Guided Bioresorbable Acoustic Hydrogel Microrobots,” Science Robotics 9, no. 97 (2024): eadp3593.

[117] B. Hao, X. Wang, Y. Dong, et al., “Focused Ultrasound Enables Selective Actuation and Newton-Level Force Output of Untethered Soft Robots,” Nature Communications 15, no. 1 (2024): 5197.

[118] N. J. Greenidge, B. Calmé, A. C. Moldovan, et al., “Harnessing the Oloid Shape in Magnetically Driven Robots to Enable High-Resolution Ultrasound Imaging,” Science Robotics 10, no. 100 (2025): eadq4198.

[119] Q. Zeng, G. Li, and W. Chen, “Ultrasound-Activatable and Skin-Associated Minimally Invasive Microdevices for Smart Drug Delivery and Diagnosis,” Advanced Drug Delivery Reviews 203 (2023): 115133.

[120] D. Xu, Y. Wang, C. Liang, Y. You, S. Sanchez, and X. Ma, “Self-Propelled Micro/Nanomotors for On-Demand Biomedical Cargo Transportation,” Small 16, no. 27 (2020): e1902464.

[121] J. Li, S. Thamphiwatana, W. Liu, et al., “Enteric Micromotor Can Selectively Position and Spontaneously Propel in the Gastrointestinal Tract,” ACS Nano 10, no. 10 (2016): 9536–9542.

[122] W. Gao, A. Uygun, and J. Wang, “Hydrogen-Bubble-Propelled Zinc-Based Microrockets in Strongly Acidic Media,” Journal of the American Chemical Society 134, no. 2 (2012): 897–900.

[123] J. Li, P. Angsantikul, W. Liu, et al., “Micromotors Spontaneously Neutralize Gastric Acid for pH-Responsive Payload Release,” Angewandte Chemie International Edition 56, no. 8 (2017): 2156–2161.

[124] A. M. Pourrahimi and M. Pumera, “Multifunctional and Self-Propelled Spherical Janus Nano/Micromotors: Recent Advances,” Nanoscale 10, no. 35 (2018): 16398–16415.

[125] H. Su, S. Li, G. Z. Yang, and K. Qian, “Janus Micro/Nanorobots in Biomedical Applications,” Advanced Healthcare Materials 12, no. 16 (2023): e2202391.

[126] E. Karshalev, Y. Zhang, B. Esteban-Fernández de Ávila, et al., “Micromotors for Active Delivery of Minerals Toward the Treatment of Iron Deficiency Anemia,” Nano Letters 19, no. 11 (2019): 7816–7826.

[127] A. K. Kubba and K. R. Palmer, “Role of Endoscopic Injection Therapy in the Treatment of Bleeding Peptic Ulcer,” Journal of British Surgery 83, no. 4 (1996): 461–468.

[128] N. I. Church and K. R. Palmer, “Injection Therapy for Endoscopic Haemostasis,” Best Practice & Research Clinical Gastroenterology 14, no. 3 (2000): 427–441.

[129] D. Libânio, P. Pimentel-Nunes, B. Bastiaansen, et al., “Endoscopic Submucosal Dissection Techniques and Technology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review,” Endoscopy 55, no. 4 (2023): 361–389.

[130] C. P. Gyawali and R. Fass, “Management of Gastroesophageal Reflux Disease,” Gastroenterology 154, no. 2 (2018): 302–318.

[131] B. S. Kushner, M. M. Awad, D. J. Mikami, B. B. Chand, C. J. Wai, and K. M. Murayama, “Endoscopic Treatments for Gerd,” Annals of the New York Academy of Sciences 1482, no. 1 (2020): 121–129.

[132] B. E. Herman, S. Baum, J. Denobile, and R. J. Volpe, “Massive Bleeding From Rectal Varices,” American Journal of Gastroenterology 88, no. 6 (1993): 939–942.

[133] X. Wang, X. Wu, Q. Wen, B. Cui, and F. Zhang, “Shifting Paradigms in Hemorrhoid Management: The Emergence and Impact of Cap-Assisted Endoscopic Sclerotherapy,” Journal of Clinical Medicine 13, no. 23 (2024): 7284.

[134] G. Traverso, C. M. Schoellhammer, A. Schroeder, et al., “Microneedles for Drug Delivery via the Gastrointestinal Tract,” Journal of Pharmaceutical Sciences 104, no. 2 (2015): 362–367.

[135] J. Byrne, H. W. Huang, J. C. McRae, et al., “Devices for Drug Delivery in the Gastrointestinal Tract: A Review of Systems Physically Interacting With the Mucosa for Enhanced Delivery,” Advanced Drug Delivery Reviews 177 (2021): 113926.

[136] A. Abramson, E. Caffarel-Salvador, M. Khang, et al., “An Ingestible Self-Orienting System for Oral Delivery of Macromolecules,” Science 363, no. 6427 (2019): 611–615.

[137] A. Abramson, M. R. Frederiksen, A. Vegge, et al., “Oral Delivery of Systemic Monoclonal Antibodies, Peptides and Small Molecules Using Gastric Auto-Injectors,” Nature Biotechnology 40, no. 1 (2022): 103–109.

[138] A. Abramson, E. Caffarel-Salvador, V. Soares, et al., “A Luminal Unfolding Microneedle Injector for Oral Delivery of Macromolecules,” Nature Medicine 25, no. 10 (2019): 1512–1518.

[139] T. Nakano, C. Sato, T. Sakurai, T. Kamei, A. Nakagawa, and N. Ohuchi, “Use of Water Jet Instruments in Gastrointestinal Endoscopy,” World Journal of Gastrointestinal Endoscopy 8, no. 3 (2016): 122–127.

[140] M. Pioche, V. Lépilliez, P. Déprez, et al., “High Pressure Jet Injection of Viscous Solutions for Endoscopic Submucosal Dissection (ESD): First Clinical Experience,” Endoscopy International Open 03, no. 4 (2015): E368–E372.

[141] A. K. Kamboj, P. Hoversten, and C. L. Leggett, “Upper Gastrointestinal Bleeding: Etiologies and Management,” Mayo Clinic Proceedings 94, no. 4 (2019): 697–703.

[142] F. Zhang, Z. Li, C. Chen, et al., “Biohybrid Microalgae Robots: Design, Fabrication, Materials, and Applications,” Advanced Materials 36, no. 3 (2024): e2303714.

[143] K. Y. Wan and R. E. Goldstein, “Coordinated Beating of Algal Flagella Is Mediated by Basal Coupling,” Proceedings of the National Academy of Sciences 113, no. 20 (2016): E2784–E2793.

[144] V. F. Geyer, F. Jülicher, J. Howard, and B. M. Friedrich, “Cell-Body Rocking Is a Dominant Mechanism for Flagellar Synchronization in a Swimming Alga,” Proceedings of the National Academy of Sciences 110, no. 45 (2013): 18058–18063.

[145] W. Xiong, Y. Peng, W. Ma, et al., “Microalgae-Material Hybrid for Enhanced Photosynthetic Energy Conversion: A Promising Path Towards Carbon Neutrality,” National Science Review 10, no. 10 (2023): nwad200.

[146] M. May, “Why Drug Delivery Is the Key to New Medicines,” Nature Medicine 28, no. 6 (2022): 1100–1102.

[147] F. Zhang, Z. Li, Y. Duan, et al., “Gastrointestinal Tract Drug Delivery Using Algae Motors Embedded in a Degradable Capsule,” Science Robotics 7, no. 70 (2022): eabo4160.

[148] F. Zhang, Z. Li, Y. Duan, et al., “Extremophile-Based Biohybrid Micromotors for Biomedical Operations in Harsh Acidic Environments,” Science Advances 8, no. 51 (2022): eade6455.

[149] T. J. Böddeker, S. Karpitschka, C. T. Kreis, Q. Magdelaine, and O. Bäumchen, “Dynamic Force Measurements on Swimming Chlamydomonas Cells Using Micropipette Force Sensors,” Journal of the Royal Society Interface 17, no. 162 (2020): 20190580.

[150] P. C. Kashyap, A. Marcobal, L. K. Ursell, et al., “Complex Interactions Among Diet, Gastrointestinal Transit, and Gut Microbiota in Humanized Mice,” Gastroenterology 144, no. 5 (2013): 967–977.

[151] K. Parikh, A. Antanaviciute, D. Fawkner-Corbett, et al., “Colonic Epithelial Cell Diversity in Health and Inflammatory Bowel Disease,” Nature 567, no. 7746 (2019): 49–55.

[152] Y. Qiao, C. He, Y. Xia, D. K. W. Ocansey, and F. Mao, “Intestinal Mucus Barrier: A Potential Therapeutic Target for IBD,” Autoimmunity Reviews 24, no. 2 (2025): 103717.

[153] Q. Lian, S. Yan, Q. Yin, et al., “TRIM34 Attenuates Colon Inflammation and Tumorigenesis by Sustaining Barrier Integrity,” Cellular & Molecular Immunology 18, no. 2 (2021): 350–362.

[154] X. Wu, W. Wu, J. Nam, L. Rong, and K. Han, “Intestinal Retentive Delivery System for Improved Disease Therapy,” Journal of Controlled Release 384 (2025): 113903.

[155] J. Smart, “The Basics and Underlying Mechanisms of Mucoadhesion,” Advanced Drug Delivery Reviews 57, no. 11 (2005): 1556–1568.

[156] R. Kulkarni, S. Fanse, and D. J. Burgess, “Mucoadhesive Drug Delivery Systems: A Promising Non-Invasive Approach to Bioavailability Enhancement. Part I: Biophysical Considerations,” Expert Opinion on Drug Delivery 20, no. 3 (2023): 395–412.

[157] R. Kulkarni, S. Fanse, and D. J. Burgess, “Mucoadhesive Drug Delivery Systems: A Promising Noninvasive Approach to Bioavailability Enhancement. Part II: Formulation Considerations,” Expert Opinion on Drug Delivery 20, no. 3 (2023): 413–434.

[158] E. Taipaleenmäki and B. Städler, “Recent Advancements in Using Polymers for Intestinal Mucoadhesion and Mucopenetration,” Macromolecular Bioscience 20, no. 3 (2020): e1900342.

[159] I. Marafini, S. Sedda, V. Dinallo, and G. Monteleone, “Inflammatory Cytokines: From Discoveries to Therapies in IBD,” Expert Opinion on Biological Therapy 19, no. 11 (2019): 1207–1217.

[160] B. Tirosh, N. Khatib, Y. Barenholz, A. Nissan, and A. Rubinstein, “Transferrin As a Luminal Target for Negatively Charged Liposomes in the Inflamed Colonic Mucosa,” Molecular Pharmaceutics 6, no. 4 (2009): 1083–1091.

[161] M. R. Scheenstra, R. M. van Harten, E. J. A. Veldhuizen, H. P. Haagsman, and M. Coorens, “Cathelicidins Modulate TLR-Activation and Inflammation,” Frontiers in Immunology 11 (2020): 1137.

[162] R. N. Cunliffe, M. Kamal, F. R. A. J. Rose, P. D. James, and Y. R. Mahida, “Expression of Antimicrobial Neutrophil Defensins in Epithelial Cells of Active Inflammatory Bowel Disease Mucosa,” Journal of Clinical Pathology 55, no. 4 (2002): 298–304.

[163] J. D. Schulzke, S. Ploeger, M. Amasheh, et al., “Epithelial Tight Junctions in Intestinal Inflammation,” Annals of the New York Academy of Sciences 1165 (2009): 294–300.

[164] L. Hong, G. Chen, Z. Cai, et al., “Balancing Microthrombosis and Inflammation via Injectable Protein Hydrogel for Inflammatory Bowel Disease,” Advanced Science 9, no. 20 (2022): 2200281.

[165] P. Zhao, X. Xia, X. Xu, et al., “Nanoparticle-Assembled Bioadhesive Coacervate Coating With Prolonged Gastrointestinal Retention for Inflammatory Bowel Disease Therapy,” Nature Communications 12, no. 1 (2021): 7162.

[166] Y. Wang, Y. Zhang, P. Wang, et al., “Intestinal Colonized Silkworm Chrysalis-Like Probiotic Composites for Multi-Crossed Comprehensive Synergistic Therapy of Inflammatory Bowel Disease,” Small 20, no. 29 (2024): e2310851.

[167] B. Ying, K. Nan, Q. Zhu, et al., “An Electroadhesive Hydrogel Interface Prolongs Porcine Gastrointestinal Mucosal Theranostics,” Science Translational Medicine 17, no. 787 (2025): eadq1975.

[168] T. Xu, X. Ning, J. Wu, et al., “Metabolic Nanoregulator Remodels Gut Microenvironment for Treatment of Inflammatory Bowel Disease,” ACS Nano 18, no. 9 (2024): 7123–7135.

[169] M. Carone, M. R. Spalinger, R. A. Gaultney, et al., “Temperature-Triggered In Situ Forming Lipid Mesophase Gel for Local Treatment of Ulcerative Colitis,” Nature Communications 14, no. 1 (2023): 3489.

[170] Y. Zhang, C. Zhou, B. Tian, et al., “3D Printed Spiral Tube-Like Cellulose Scaffold for Oral Delivery of Probiotics,” Science Advances 10, no. 34 (2024): eadp3654.

[171] Q. Huang, Y. Yang, Y. Zhu, et al., “Oral Metal-Free Melanin Nanozymes for Natural and Durable Targeted Treatment of Inflammatory Bowel Disease (IBD),” Small 19, no. 19 (2023): e2207350.

[172] R. Li, Y. Fan, L. Liu, et al., “Ultrathin Hafnium Disulfide Atomic Crystals With Ros-Scavenging and Colon-Targeting Capabilities for Inflammatory Bowel Disease Treatment,” ACS Nano 16, no. 9 (2022): 15026–15041.

[173] T. T. Jubeh, Y. Barenholz, and A. Rubinstein, “Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes,” Pharmaceutical Research 21, no. 3 (2004): 447–453.

[174] A. Beloqui, R. Coco, M. Alhouayek, et al., “Budesonide-Loaded Nanostructured Lipid Carriers Reduce Inflammation in Murine Dss-Induced Colitis,” International Journal of Pharmaceutics 454, no. 2 (2013): 775–783.

[175] J. Li, T. Wang, A. R. Kirtane, et al., “Gastrointestinal Synthetic Epithelial Linings,” Science Translational Medicine 12, no. 558 (2020): eabc0441.

[176] A. Bernkop-Schnürch, “Thiomers: A New Generation of Mucoadhesive Polymers,” Advanced Drug Delivery Reviews 57, no. 11 (2005): 1569–1582.

[177] X. Wang, Z. Cao, M. Zhang, L. Meng, Z. Ming, and J. Liu, “Bioinspired Oral Delivery of Gut Microbiota by Self-Coating With Biofilms,” Science Advances 6, no. 26 (2020): eabb1952.

[178] L. M. Ensign, R. Cone, and J. Hanes, “Oral Drug Delivery With Polymeric Nanoparticles: The Gastrointestinal Mucus Barriers,” Advanced Drug Delivery Reviews 64, no. 6 (2012): 557–570.

[179] R. Sender and R. Milo, “The Distribution of Cellular Turnover in the Human Body,” Nature Medicine 27, no. 1 (2021): 45–48.

[180] J. Damianos, N. Abdelnaem, and M. Camilleri, “Gut Goo: Physiology, Diet, and Therapy of Intestinal Mucus and Biofilms in Gastrointestinal Health and Disease,” Clinical Gastroenterology and Hepatology 23, no. 2 (2025): 205–215.

[181] T. Oshima and H. Miwa, “Gastrointestinal Mucosal Barrier Function and Diseases,” Journal of Gastroenterology 51, no. 8 (2016): 768–778.

[182] J. An, Y. Liu, Y. Wang, et al., “The Role of Intestinal Mucosal Barrier in Autoimmune Disease: A Potential Target,” Frontiers in Immunology 13 (2022): 871713.

[183] L. K. Borden, A. Gargava, and S. R. Raghavan, “Reversible Electroadhesion of Hydrogels to Animal Tissues for Suture-Less Repair of Cuts or Tears,” Nature Communications 12, no. 1 (2021): 4419.

[184] C. K. Roy, H. L. Guo, T. L. Sun, et al., “Self-Adjustable Adhesion of Polyampholyte Hydrogels,” Advanced Materials 27, no. 45 (2015): 7344–7348.

[185] J. Luo, X. Zhao, B. Guo, and Y. Han, “Preparation, Thermal Response Mechanisms and Biomedical Applications of Thermosensitive Hydrogels for Drug Delivery,” Expert Opinion on Drug Delivery 20, no. 5 (2023): 641–672.

[186] M. R. Dethe, P. A, H. Ahmed, M. Agrawal, U. Roy, and A. Alexander, “PCL-PEG Copolymer Based Injectable Thermosensitive Hydrogels,” Journal of Controlled Release 343 (2022): 217–236.

[187] J. Shi, L. Yu, and J. Ding, “PEG-Based Thermosensitive and Biodegradable Hydrogels,” Acta Biomaterialia 128 (2021): 42–59.

[188] Z. Yang, X. Zhou, L. Wang, et al., “Mn₃O₄ Nanozyme Loaded Thermosensitive PDLLA-PEG-PDLLA Hydrogels for the Treatment of Inflammatory Bowel Disease,” ACS Applied Materials & Interfaces 15, no. 28 (2023): 33273–33287.

[189] B. Jeong, S. W. Kim, and Y. H. Bae, “Thermosensitive Sol-Gel Reversible Hydrogels,” Advanced Drug Delivery Reviews 54, no. 1 (2002): 37–51.

[190] A. Alexander, Ajazuddin , J. Khan, S. Saraf, and S. Saraf, “Poly(Ethylene Glycol)-Poly(Lactic-Co-Glycolic Acid) Based Thermosensitive Injectable Hydrogels for Biomedical Applications,” Journal of Controlled Release 172, no. 3 (2013): 715–729.

[191] Y. Chen, J. H. Lee, M. Meng, et al., “An Overview on Thermosensitive Oral Gel Based on Poloxamer 407,” Materials 14, no. 16 (2021): 4522.

[192] B. Shriky, A. Kelly, M. Isreb, et al., “Pluronic F127 Thermosensitive Injectable Smart Hydrogels for Controlled Drug Delivery System Development,” Journal of Colloid and Interface Science 565 (2020): 119–130.

[193] X. Wei, Y. Wang, Y. Liu, et al., “Biomimetic Design Strategies for Biomedical Applications,” Matter 7, no. 3 (2024): 826–854.

[194] D. Han, R. S. Morde, S. Mariani, et al., “4D Printing of a Bioinspired Microneedle Array With Backward-Facing Barbs for Enhanced Tissue Adhesion,” Advanced Functional Materials 30, no. 11 (2020): 1909197.

[195] X. Li, W. Shan, Y. Yang, et al., “Limpet Tooth-Inspired Painless Microneedles Fabricated by Magnetic Field-Assisted 3D Printing,” Advanced Functional Materials 31, no. 5 (2021): 2003725.

[196] Y. Gong, S. Tong, X. Li, et al., “Intestinal Villi-Inspired Mathematically Base-Layer Engineered Microneedles (Imbems) for Effective Molecular Exchange During Biomarker Enrichment and Drug Deposition in Diversified Mucosa,” ACS Nano 17, no. 16 (2023): 15696–15712.

[197] W. Chen, J. Wainer, S. W. Ryoo, et al., “Dynamic Omnidirectional Adhesive Microneedle System for Oral Macromolecular Drug Delivery,” Science Advances 8, no. 1 (2022): eabk1792.

[198] L. Huang, L. Li, Y. Jiang, et al., “Tumbler-Inspired Microneedle Containing Robots: Achieving Rapid Self-Orientation and Peristalsis-Resistant Adhesion for Colonic Administration,” Advanced Functional Materials 33, no. 43 (2023): 2304276.

[199] X. Gao, J. Li, J. Li, M. Zhang, and J. Xu, “Pain-Free Oral Delivery of Biologic Drugs Using Intestinal Peristalsis-Actuated Microneedle Robots,” Science Advances 10, no. 1 (2024): eadj7067.

[200] C. Lin, Z. Huang, Q. Wang, et al., “3D Printed Bioinspired Stents With Photothermal Effects for Malignant Colorectal Obstruction,” Research; A Journal of Science and Its Applications 2022 (2022): 9825656.

[201] J. Kim, J. Yeom, Y. G. Ro, G. Na, W. Jung, and H. Ko, “Plasmonic Hydrogel Actuators for Octopus-Inspired Photo/Thermoresponsive Smart Adhesive Patch,” ACS Nano 18, no. 32 (2024): 21364–21375.

[202] I. D. Iliev, A. N. Ananthakrishnan, and C. J. Guo, “Microbiota in Inflammatory Bowel Disease: Mechanisms of Disease and Therapeutic Opportunities,” Nature Reviews Microbiology 23, no. 8 (2025): 509–524.

[203] J. Yang, D. Li, M. Zhang, G. Lin, S. Hu, and H. Xu, “From the Updated Landscape of the Emerging Biologics for IBDs Treatment to the New Delivery Systems,” Journal of Controlled Release 361 (2023): 568–591.

[204] Q. Li, L. Lin, C. Zhang, et al., “The Progression of Inorganic Nanoparticles and Natural Products for Inflammatory Bowel Disease,” Journal of Nanobiotechnology 22, no. 1 (2024): 17.

[205] P. Lei, H. Yu, J. Ma, et al., “Cell Membrane Nanomaterials Composed of Phospholipids and Glycoproteins for Drug Delivery in Inflammatory Bowel Disease: A Review,” International Journal of Biological Macromolecules 249 (2023): 126000.

[206] D. R. Plichta, D. B. Graham, S. Subramanian, and R. J. Xavier, “Therapeutic Opportunities in Inflammatory Bowel Disease: Mechanistic Dissection of Host-Microbiome Relationships,” Cell 178, no. 5 (2019): 1041–1056.

[207] K. J. Maloy and F. Powrie, “Intestinal Homeostasis and Its Breakdown in Inflammatory Bowel Disease,” Nature 474, no. 7351 (2011): 298–306.

[208] L. Lih-Brody, S. R. Powell, K. P. Collier, et al., “Increased Oxidative Stress and Decreased Antioxidant Defenses in Mucosa of Inflammatory Bowel Disease,” Digestive Diseases and Sciences 41, no. 10 (1996): 2078–2086.

[209] M. Pu, H. Cao, H. Zhang, et al., “ROS-Responsive Hydrogels: From Design and Additive Manufacturing to Biomedical Applications,” Materials Horizons 11, no. 16 (2024): 3721–3746.

[210] G. Zhang, D. Song, R. Ma, et al., “Artificial Mucus Layer Formed in Response to ROS for the Oral Treatment of Inflammatory Bowel Disease,” Science Advances 10, no. 30 (2024): eado8222.

[211] H. S. Kim, S. Lee, and D. Y. Lee, “Aurozyme: A Revolutionary Nanozyme in Colitis, Switching Peroxidase-Like to Catalase-Like Activity,” Small 19, no. 41 (2023): e2302331.

[212] T. Chen, W. Meng, Y. Li, et al., “Probiotics Armed With In Situ Mineralized Nanocatalysts and Targeted Biocoatings for Multipronged Treatment of Inflammatory Bowel Disease,” Nano Letters 24, no. 24 (2024): 7321–7331.

[213] J. Yu, S. Li, B. Xiong, et al., “Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease,” Advanced Materials 37, no. 4 (2025): e2412429.

[214] F. Dong, L. Hao, L. Wang, and Y. Huang, “Clickable Nanozyme Enhances Precise Colonization of Probiotics for Ameliorating Inflammatory Bowel Disease,” Journal of Controlled Release 373 (2024): 749–765.

[215] J. Wang, X. Lv, Y. Li, et al., “A ROS-Responsive Hydrogel That Targets Inflamed Mucosa to Relieve Ulcerative Colitis by Reversing Intestinal Mucosal Barrier Loss,” Journal of Controlled Release 377 (2025): 606–618.

[216] Y. Huang, J. Ren, and X. Qu, “Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications,” Chemical Reviews 119, no. 6 (2019): 4357–4412.

[217] Q. Wang, C. Cheng, S. Zhao, et al., “A Valence-Engineered Self-Cascading Antioxidant Nanozyme for the Therapy of Inflammatory Bowel Disease,” Angewandte Chemie International Edition 61, no. 27 (2022): e202201101.

[218] S. Zhao, Y. X. Li, Q. Y. Liu, et al., “An Orally Administered CeO@Montmorillonite Nanozyme Targets Inflammation for Inflammatory Bowel Disease Therapy,” Advanced Functional Materials 30, no. 45 (2020): 2004692.

[219] D. K. Min, Y. E. Kim, M. K. Kim, S. W. Choi, N. Park, and J. Kim, “Orally Administrated Inflamed Colon-Targeted Nanotherapeutics for Inflammatory Bowel Disease Treatment by Oxidative Stress Level Modulation in Colitis,” ACS Nano 17, no. 23 (2023): 24404–24416.

[220] J. Yang, Y. Bai, S. Shen, et al., “An Oral Nano-Antioxidant for Targeted Treatment of Inflammatory Bowel Disease by Regulating Macrophage Polarization and Inhibiting Ferroptosis of Intestinal Cells,” Chemical Engineering Journal 465 (2023): 142940.

[221] H. Yao, F. Wang, H. Chong, et al., “A Curcumin-Modified Coordination Polymers With ROS Scavenging and Macrophage Phenotype Regulating Properties for Efficient Ulcerative Colitis Treatment,” Advanced Science 10, no. 19 (2023): 2300601.

[222] Y. Yu, X. Zhao, X. Xu, et al., “Rational Design of Orally Administered Cascade Nanozyme for Inflammatory Bowel Disease Therapy,” Advanced Materials 35, no. 44 (2023): e2304967.

[223] B. Lamas, N. Martins Breyner, and E. Houdeau, “Impacts of Foodborne Inorganic Nanoparticles on the Gut Microbiota-Immune Axis: Potential Consequences for Host Health,” Particle and Fibre Toxicology 17, no. 1 (2020): 19.

[224] Y. Ma, J. Zhao, L. Cheng, et al., “Versatile Carbon Dots With Superoxide Dismutase-Like Nanozyme Activity and Red Fluorescence for Inflammatory Bowel Disease Therapeutics,” Carbon 204 (2023): 526–537.

[225] L. Wang, B. Zhu, Y. Deng, et al., “Biocatalytic and Antioxidant Nanostructures for ROS Scavenging and Biotherapeutics,” Advanced Functional Materials 31, no. 31 (2021): 2101804.

[226] S. Zhou, H. Cai, X. He, Z. Tang, and S. Lu, “Enzyme-Mimetic Antioxidant Nanomaterials for ROS Scavenging: Design, Classification, and Biological Applications,” Coordination Chemistry Reviews 500 (2024): 215536.

[227] J. Xu, T. Chu, T. Yu, et al., “Design of Diselenide-Bridged Hyaluronic Acid Nano-Antioxidant for Efficient ROS Scavenging to Relieve Colitis,” ACS Nano 16, no. 8 (2022): 13037–13048.

[228] S. Gou, Q. Chen, Y. Liu, et al., “Green Fabrication of Ovalbumin Nanoparticles as Natural Polyphenol Carriers for Ulcerative Colitis Therapy,” ACS Sustainable Chemistry & Engineering 6, no. 10 (2018): 12658–12667.

[229] Y. Fei, S. Zhang, S. Han, et al., “The Role of Dihydroresveratrol in Enhancing the Synergistic Effect of Ligilactobacillus Salivarius li01 and Resveratrol in Ameliorating Colitis in Mice,” Research; A Journal of Science and Its Applications 2022 (2022): 9863845.

[230] S. Habtemariam, “Berberine and Inflammatory Bowel Disease: A Concise Review,” Pharmacological Research 113, no. Pt A (2016): 592–599.

[231] Z. Chen, M. A. Farag, Z. Zhong, et al., “Multifaceted Role of Phyto-Derived Polyphenols in Nanodrug Delivery Systems,” Advanced Drug Delivery Reviews 176 (2021): 113870.

[232] C. Zhao, J. Yang, M. Chen, et al., “Synthetic Lignin-Derived Therapeutic Nano Reagent as Intestinal pH-Sensitive Drug Carriers Capable of Bypassing the Gastric Acid Environment for Colitis Treatment,” ACS Nano 17, no. 1 (2023): 811–824.

[233] Y. Wang, J. Zhang, Y. Zhao, et al., “Innovations and Challenges of Polyphenol-Based Smart Drug Delivery Systems,” Nano Research 15, no. 9 (2022): 8156–8184.

[234] M. Vaghari-Tabari, F. Alemi, M. Zokaei, et al., “Polyphenols and Inflammatory Bowel Disease: Natural Products With Therapeutic Effects?,” Critical Reviews in Food Science and Nutrition 64, no. 13 (2024): 4155–4178.

[235] Y. Wang, Z. Li, Y. Bao, et al., “Colon-Targeted Delivery of Polyphenols: Construction Principles, Targeting Mechanisms and Evaluation Methods,” Critical Reviews in Food Science and Nutrition 65, no. 1 (2025): 64–86.

[236] Q. Pan, L. Xie, H. Zhu, et al., “Curcumin-Incorporated EGCG-Based Nano-Antioxidants Alleviate Colon and Kidney Inflammation via Antioxidant and Anti-Inflammatory Therapy,” Regenerative Biomaterials 11 (2024): rbae122.

[237] Q. Pan, L. Xie, P. Cai, et al., “Acid-Resistant Nano-Antioxidants Based on Epigallocatechin Gallate Alleviate Acute Intestinal and Kidney Inflammation,” ACS Applied Materials & Interfaces 16, no. 35 (2024): 46090–46101.

[238] X. Fan, Z. Zhang, W. Gao, et al., “An Engineered Butyrate-Derived Polymer Nanoplatform as a Mucosa-Healing Enhancer Potentiates the Therapeutic Effect of Magnolol in Inflammatory Bowel Disease,” ACS Nano 18, no. 1 (2024): 229–244.

[239] Z. Deng, W. Ma, C. Ding, et al., “Metal Polyphenol Network/Cerium Oxide Artificial Enzymes Therapeutic Nanoplatform for MRI/CT-Aided Intestinal Inflammation Management,” Nano Today 53 (2023): 102044.

[240] Y. Zhu, Z. Fang, J. Bai, et al., “Orally Administered Functional Polyphenol-Nanozyme-Armored Probiotics for Enhanced Amelioration of Intestinal Inflammation and Microbiota Dysbiosis,” Advanced Science 12, no. 17 (2025): e2411939.

[241] Z. Wang, Z. X. Wang, K. F. Xu, et al., “A Metal-Polyphenol-Based Antidepressant for Alleviating Colitis-Associated Mental Disorders,” Advanced Materials 37, no. 3 (2025): e2410993.

[242] H. Chu, A. Khosravi, I. P. Kusumawardhani, et al., “Gene-Microbiota Interactions Contribute to the Pathogenesis of Inflammatory Bowel Disease,” Science 352, no. 6289 (2016): 1116–1120.

[243] R. White, T. Atherly, B. Guard, et al., “Randomized, Controlled Trial Evaluating the Effect of Multi-Strain Probiotic on the Mucosal Microbiota in Canine Idiopathic Inflammatory Bowel Disease,” Gut Microbes 8, no. 5 (2017): 451–466.

[244] M. V. Prosberg, S. I. Halkjær, B. Lo, et al., “Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova: A Randomised, Double-Blinded, Placebo-Controlled Clinical Trial [The Procto Trial],” Journal of Crohn's and Colitis 18, no. 11 (2024): 1879–1893.

[245] R. Bibiloni, R. N. Fedorak, G. W. Tannock, et al., “Vsl#3 Probiotic-Mixture Induces Remission in Patients With Active Ulcerative Colitis,” American Journal of Gastroenterology 100, no. 7 (2005): 1539–1546.

[246] J. A. Imlay, “How Oxygen Damages Microbes: Oxygen Tolerance and Obligate Anaerobiosis,” Advances in Microbial Physiology 46 (2002): 111–153.

[247] G. Tomasello, M. Mazzola, A. Leone, et al., “Nutrition, Oxidative Stress and Intestinal Dysbiosis: Influence of Diet on Gut Microbiota in Inflammatory Bowel Diseases,” Biomedical Papers 160, no. 4 (2016): 461–466.

[248] S. Ashique, N. Mishra, A. Garg, et al., “Recent Updates on Correlation Between Reactive Oxygen Species and Synbiotics for Effective Management of Ulcerative Colitis,” Frontiers in Nutrition 10 (2023): 1126579.

[249] X. Jiang, X. Hao, L. Jing, et al., “Recent Applications of Click Chemistry in Drug Discovery,” Expert Opinion on Drug Discovery 14, no. 8 (2019): 779–789.

[250] T. Fang and S. Liu, “Metal-Phenolic Network Directed Coating of Single Probiotic Cell Followed by Photoinitiated Thiol-Ene Click Fortification to Enhance Oral Therapy,” Small 20, no. 19 (2024): e2308146.

[251] C. Zhang, Z. Yu, J. Zhao, H. Zhang, Q. Zhai, and W. Chen, “Colonization and Probiotic Function of Bifidobacterium Longum,” Journal of Functional Foods 53 (2019): 157–165.

[252] F. Cao, L. Jin, Y. Gao, et al., “Artificial-Enzymes-Armed Bifidobacterium Longum Probiotics for Alleviating Intestinal Inflammation and Microbiota Dysbiosis,” Nature Nanotechnology 18, no. 6 (2023): 617–627.

[253] B. D. McDonald, E. C. Dyer, and D. T. Rubin, “IL-23 Monoclonal Antibodies for IBD: So Many, so Different?,” Journal of Crohn's and Colitis 16, no. Suppl_2 (2022): ii42–ii53.

[254] A. Stallmach, R. Atreya, P. C. Grunert, J. Stallhofer, J. de Laffolie, and C. Schmidt, “Treatment Strategies in Inflammatory Bowel Diseases,” Deutsches Ärzteblatt international 120, no. 45 (2023): 768–778.

[255] M. Zu, Y. Ma, B. Cannup, et al., “Oral Delivery of Natural Active Small Molecules by Polymeric Nanoparticles for the Treatment of Inflammatory Bowel Diseases,” Advanced Drug Delivery Reviews 176 (2021): 113887.

[256] S. Zhang, R. Langer, and G. Traverso, “Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease,” Nano Today 16 (2017): 82–96.

[257] S. Hua, E. Marks, J. J. Schneider, and S. Keely, “Advances in Oral Nano-Delivery Systems for Colon Targeted Drug Delivery in Inflammatory Bowel Disease: Selective Targeting to Diseased Versus Healthy Tissue,” Nanomedicine: Nanotechnology, Biology and Medicine 11, no. 5 (2015): 1117–1132.

[258] X. Wu, J. J. Hu, and J. Yoon, “Cell Membrane as a Promising Therapeutic Target: From Materials Design to Biomedical Applications,” Angewandte Chemie International Edition 63, no. 18 (2024): e202400249.

[259] Y. Liu, J. Luo, X. Chen, W. Liu, and T. Chen, “Cell Membrane Coating Technology: A Promising Strategy for Biomedical Applications,” Nano-Micro Letters 11, no. 1 (2019): 100.

[260] K. Zhang, J. Guo, W. Yan, and L. Xu, “Macrophage Polarization in Inflammatory Bowel Disease,” Cell Communication and Signaling 21, no. 1 (2023): 367.

[261] X. Pan, Q. Zhu, L. L. Pan, and J. Sun, “Macrophage Immunometabolism in Inflammatory Bowel Diseases: From Pathogenesis to Therapy,” Pharmacology & Therapeutics 238 (2022): 108176.

[262] B. Xiao, H. Laroui, S. Ayyadurai, et al., “Mannosylated Bioreducible Nanoparticle-Mediated Macrophage-Specific TNF-α RNA Interference for IBD Therapy,” Biomaterials 34, no. 30 (2013): 7471–7482.

[263] J. Zhang, C. Tang, and C. Yin, “Galactosylated Trimethyl Chitosan-Cysteine Nanoparticles Loaded With Map4k4 siRNA for Targeting Activated Macrophages,” Biomaterials 34, no. 14 (2013): 3667–3677.

[264] K. Ley, J. Rivera-Nieves, W. J. Sandborn, and S. Shattil, “Integrin-Based Therapeutics: Biological Basis, Clinical Use and New Drugs,” Nature Reviews Drug Discovery 15, no. 3 (2016): 173–183.

[265] C. J. Tyler, M. Guzman, L. R. Lundborg, et al., “Antibody Secreting Cells Are Critically Dependent on Integrin α4β7/MAdCAM-1 for Intestinal Recruitment and Control of the Microbiota During Chronic Colitis,” Mucosal Immunology 15, no. 1 (2022): 109–119.

[266] L. Huang, W. Hu, L. Q. Huang, et al., “Two-Birds-One-Stone” Oral Nanotherapeutic Designed to Target Intestinal Integrins and Regulate Redox Homeostasis for Uc Treatment,” Science Advances 10, no. 30 (2024): eado7438.

[267] W. Li, J. Cai, Y. Gu, et al., “Novel pH-Responsive and CD44-Targeting Silica Nanoparticles for Inflammatory Bowel Disease Therapy,” Chemical Engineering Journal 513 (2025): 163017.

[268] Y. Duan, E. Zhang, R. H. Fang, W. Gao, and L. Zhang, “Capsulated Cellular Nanosponges for the Treatment of Experimental Inflammatory Bowel Disease,” ACS Nano 17, no. 16 (2023): 15893–15904.

[269] S. Lin, S. Han, X. Wang, et al., “Oral Microto-Nano Genome-Editing System Enabling Targeted Delivery and Conditional Activation of CRISPR-Cas9 for Gene Therapy of Inflammatory Bowel Disease,” ACS Nano 18, no. 37 (2024): 25657–25670.

[270] Q. Fan, Z. Yang, Y. Li, Y. Cheng, and Y. Li, “Polycatechol Mediated Small Interfering RNA Delivery for the Treatment of Ulcerative Colitis,” Advanced Functional Materials 31, no. 24 (2021): 2101646.

[271] J. Ouyang, B. Deng, B. Zou, et al., “Oral Hydrogel Microbeads-Mediated In Situ Synthesis of Selenoproteins for Regulating Intestinal Immunity and Microbiota,” Journal of the American Chemical Society 145, no. 22 (2023): 12193–12205.

[272] B. Park, G. Han, D. Y. Jin, et al., “Mucoadhesive Mesalamine Prodrug Nanoassemblies to Target Intestinal Macrophages for the Treatment of Inflammatory Bowel Disease,” ACS Nano 18, no. 25 (2024): 16297–16311.

[273] S. Gou, Y. Huang, Y. Wan, et al., “Multi-Bioresponsive Silk Fibroin-Based Nanoparticles With on-Demand Cytoplasmic Drug Release Capacity for CD44-targeted Alleviation of Ulcerative Colitis,” Biomaterials 212 (2019): 39–54.

[274] S. Y. Vafaei, M. Esmaeili, M. Amini, F. Atyabi, S. N. Ostad, and R. Dinarvand, “Self Assembled Hyaluronic Acid Nanoparticles as a Potential Carrier for Targeting the Inflamed Intestinal Mucosa,” Carbohydrate Polymers 144 (2016): 371–381.

[275] L. Cao, D. Duan, J. Peng, et al., “Oral Enzyme-Responsive Nanoprobes for Targeted Theranostics of Inflammatory Bowel Disease,” Journal of Nanobiotechnology 22, no. 1 (2024): 484.

[276] A. Marinho, C. Nunes, and S. Reis, “Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation,” Biomolecules 11, no. 10 (2021): 1518.

[277] C. Hu, Y. Wang, S. Liao, et al., “Neutrophil-Macrophage Hybrid Membrane-Coated Prussian Blue Nanozyme for Ulcerative Colitis Treatment and Mechanistic Insights,” Journal of Nanobiotechnology 23, no. 1 (2025): 43.

[278] G. Sharma, A. R. Sharma, M. Bhattacharya, S. S. Lee, and C. Chakraborty, “CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases,” Molecular Therapy 29, no. 2 (2021): 571–586.

[279] M. H. Lee, J. I. Shin, J. W. Yang, et al., “Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review,” International Journal of Molecular Sciences 23, no. 3 (2022): 1337.

[280] V. Limanskiy, A. Vyas, L. S. Chaturvedi, and D. Vyas, “Harnessing the Potential of Gene Editing Technology Using CRISPR in Inflammatory Bowel Disease,” World Journal of Gastroenterology 25, no. 18 (2019): 2177–2187.

[281] Z. Pan, K. Xu, G. Huang, et al., “Pyroptotic-Spatiotemporally Selective Delivery of siRNA Against Pyroptosis and Autoimmune Diseases,” Advanced Materials 36, no. 38 (2024): e2407115.

[282] A. Seki and S. Rutz, “Optimized RNP Transfection for Highly Efficient CRISPR/Cas9-mediated Gene Knockout in Primary T Cells,” Journal of Experimental Medicine 215, no. 3 (2018): 985–997.

[283] J. Shinn, J. Lee, S. A. Lee, et al., “Oral Nanomedicines for siRNA Delivery to Treat Inflammatory Bowel Disease,” Pharmaceutics 14, no. 9 (2022): 1969.

[284] S. El-Andaloussi, Y. Lee, S. Lakhal-Littleton, et al., “Exosome-Mediated Delivery of siRNA In Vitro and In Vivo,” Nature Protocols 7, no. 12 (2012): 2112–2126.

[285] J. Van Hoeck, K. Braeckmans, S. C. De Smedt, and K. Raemdonck, “Non-Viral siRNA Delivery to T Cells: Challenges and Opportunities in Cancer Immunotherapy,” Biomaterials 286 (2022): 121510.

[286] A. Biscans, A. Coles, R. Haraszti, et al., “Diverse Lipid Conjugates for Functional Extra-Hepatic siRNA Delivery In Vivo,” Nucleic Acids Research 47, no. 3 (2019): 1082–1096.

[287] Y. Du, Y. Liu, J. Hu, X. Peng, and Z. Liu, “CRISPR/Cas9 Systems: Delivery Technologies and Biomedical Applications,” Asian Journal of Pharmaceutical Sciences 18, no. 6 (2023): 100854.

[288] Y. Dong, D. J. Siegwart, and D. G. Anderson, “Strategies, Design, and Chemistry in siRNA Delivery Systems,” Advanced Drug Delivery Reviews 144 (2019): 133–147.

[289] D. Mun, J. Y. Kang, H. Kim, N. Yun, and B. Joung, “Small Extracellular Vesicle-Mediated CRISPR-Cas9 RNP Delivery for Cardiac-Specific Genome Editing,” Journal of Controlled Release 370 (2024): 798–810.

[290] S. Zhang, J. Shen, D. Li, and Y. Cheng, “Strategies in the Delivery of Cas9 Ribonucleoprotein for CRISPR/Cas9 Genome Editing,” Theranostics 11, no. 2 (2021): 614–648.

[291] J. Gilleron, W. Querbes, A. Zeigerer, et al., “Image-Based Analysis of Lipid Nanoparticle-Mediated siRNA Delivery, Intracellular Trafficking and Endosomal Escape,” Nature Biotechnology 31, no. 7 (2013): 638–646.

[292] S. Y. Wu, G. Lopez-Berestein, G. A. Calin, and A. K. Sood, “RNAi Therapies: Drugging the Undruggable,” Science Translational Medicine 6, no. 240 (2014): 240.

[293] S. F. Dowdy, “Overcoming Cellular Barriers for RNA Therapeutics,” Nature Biotechnology 35, no. 3 (2017): 222–229.

[294] Y. Q. Lin, K. K. Feng, J. Y. Lu, et al., “CRISPR/Cas9-Based Application for Cancer Therapy: Challenges and Solutions for Non-Viral Delivery,” Journal of Controlled Release 361 (2023): 727–749.

[295] J. Yang, M. Peng, S. Tan, et al., “Calcium Tungstate Microgel Enhances the Delivery and Colonization of Probiotics During Colitis via Intestinal Ecological Niche Occupancy,” ACS Central Science 9, no. 7 (2023): 1327–1341.

[296] H. Huldani, R. Margiana, F. Ahmad, et al., “Immunotherapy of Inflammatory Bowel Disease (IBD) Through Mesenchymal Stem Cells,” International Immunopharmacology 107 (2022): 108698.

[297] S. Wang, B. Lei, E. Zhang, et al., “Targeted Therapy for Inflammatory Diseases With Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics,” International Journal of Nanomedicine 17 (2022): 1757–1781.

[298] Y. Wang, B. Huang, T. Jin, D. K. W. Ocansey, J. Jiang, and F. Mao, “Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy,” Frontiers in Immunology 13 (2022): 835005.

[299] A. B. Dietz, E. J. Dozois, J. G. Fletcher, et al., “Autologous Mesenchymal Stem Cells, Applied in a Bioabsorbable Matrix, for Treatment of Perianal Fistulas in Patients With Crohn's Disease,” Gastroenterology 153, no. 1 (2017): 59–62.e2.

[300] J. Panés, D. García-Olmo, G. Van Assche, et al., “Long-Term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease,” Gastroenterology 154, no. 5 (2018): 1334–1342.e4.

[301] Z. W. Meng and D. C. Baumgart, “Darvadstrocel for the Treatment of Perianal Fistulas in Crohn's Disease,” Expert Review of Gastroenterology & Hepatology 14, no. 6 (2020): 405–410.

[302] L. Li, Z.-C. Yao, A. Parian, et al., “A Nanofiber-Hydrogel Composite Improves Tissue Repair in a Rat Model of Crohn's Disease Perianal Fistulas,” Science Advances 9, no. 1 (2023): eade1067.

[303] E. Munoz-Perez, M. Igartua, E. Santos-Vizcaino, and R. M. Hernandez, “3D-Printed Laponite/Alginate Hydrogel-Based Suppositories as Innovative Platforms for At-Msc Secretome Delivery in IBD Treatment,” International Journal of Biological Macromolecules 318, no. Pt 2 (2025): 145104.

[304] M. F. Neurath, B. E. Sands, and F. Rieder, “Cellular Immunotherapies and Immune Cell Depleting Therapies in Inflammatory Bowel Diseases: The Next Magic Bullet?,” Gut 74, no. 1 (2024): 9–14.

[305] V. C. Ibekwe, H. M. Fadda, E. L. McConnell, M. K. Khela, D. F. Evans, and A. W. Basit, “Interplay Between Intestinal pH, Transit Time and Feed Status on the In Vivo Performance of pH Responsive Ileo-Colonic Release Systems,” Pharmaceutical Research 25, no. 8 (2008): 1828–1835.

[306] F. Liu, P. Moreno, and A. W. Basit, “A Novel Double-Coating Approach for Improved pH-Triggered Delivery to the Ileo-Colonic Region of the Gastrointestinal Tract,” European Journal of Pharmaceutics and Biopharmaceutics 74, no. 2 (2010): 311–315.

[307] F. J. O. Varum, G. B. Hatton, A. C. Freire, and A. W. Basit, “A Novel Coating Concept for Ileo-Colonic Drug Targeting: Proof of Concept in Humans Using Scintigraphy,” European Journal of Pharmaceutics and Biopharmaceutics 84, no. 3 (2013): 573–577.

[308] H. A. Merchant, A. Goyanes, N. Parashar, and A. W. Basit, “Predicting the Gastrointestinal Behaviour of Modified-Release Products: Utility of a Novel Dynamic Dissolution Test Apparatus Involving the Use of Bicarbonate Buffers,” International Journal of Pharmaceutics 475, no. 1–2 (2014): 585–591.

[309] R. C. A. Schellekens, F. Stellaard, D. Mitrovic, F. E. Stuurman, J. G. W. Kosterink, and H. W. Frijlink, “Pulsatile Drug Delivery to Ileo-Colonic Segments by Structured Incorporation of Disintegrants in pH-Responsive Polymer Coatings,” Journal of Controlled Release 132, no. 2 (2008): 91–98.

[310] R. C. A. Schellekens, F. Stellaard, G. G. Olsder, H. J. Woerdenbag, H. W. Frijlink, and J. G. W. Kosterink, “Oral Ileocolonic Drug Delivery by the Colopulse-System: A Bioavailability Study in Healthy Volunteers,” Journal of Controlled Release 146, no. 3 (2010): 334–340.

[311] L. Chen, C. Xia, Z. Zhao, H. Fu, and Y. Chen, “AI-Driven Sensing Technology: Review,” Sensors 24, no. 10 (2024): 2958.

[312] A. S. Luis and G. C. Hansson, “Intestinal Mucus and Their Glycans: A Habitat for Thriving Microbiota,” Cell Host & Microbe 31, no. 7 (2023): 1087–1100.

[313] C. Song, Z. Chai, S. Chen, H. Zhang, X. Zhang, and Y. Zhou, “Intestinal Mucus Components and Secretion Mechanisms: What We Do and Do Not Know,” Experimental & Molecular Medicine 55, no. 4 (2023): 681–691.

[314] L. Wittner, L. Wagener, J. J. Wiese, et al., “Proteolytic Activity of the Paracaspase malt1 Is Involved in Epithelial Restitution and Mucosal Healing,” International Journal of Molecular Sciences 24, no. 8 (2023): 7402.

[315] J. Vandooren, P. Goeminne, L. Boon, et al., “Neutrophils and Activated Macrophages Control Mucosal Immunity by Proteolytic Cleavage of Antileukoproteinase,” Frontiers in Immunology 9 (2018): 1154.

[316] A. Robert and B. Meunier, “How to Define a Nanozyme,” ACS Nano 16, no. 5 (2022): 6956–6959.

[317] X. Ren, D. Chen, Y. Wang, et al., “Nanozymes-Recent Development and Biomedical Applications,” Journal of Nanobiotechnology 20, no. 1 (2022): 92.

[318] R. Zhang, B. Jiang, K. Fan, L. Gao, and X. Yan, “Designing Nanozymes for In Vivo Applications,” Nature Reviews Bioengineering 2, no. 10 (2024): 849–868.

[319] J. Zhang, S. Wu, X. Lu, P. Wu, and J. Liu, “Manganese as a Catalytic Mediator for Photo-Oxidation and Breaking the pH Limitation of Nanozymes,” Nano Letters 19, no. 5 (2019): 3214–3220.

[320] L. Huang, X. H. Huang, X. Yang, et al., “Novel Nano-Drug Delivery System for Natural Products and Their Application,” Pharmacological Research 201 (2024): 107100.

[321] M. Agrawal, A. Vianello, M. Picker, et al., “Micro- and Nano-Plastics, Intestinal Inflammation, and Inflammatory Bowel Disease: A Review of the Literature,” Science of the Total Environment 953 (2024): 176228.

[322] K. Zhu, X. Liu, L. Fu, et al., “NIR-II Ratiometric Optical Theranostic Capsule for In Situ Diagnosis and Precise Therapy of Intestinal Inflammation,” ACS Nano 18, no. 51 (2024): 34912–34923.

[323] Z. Jin, Y. Zhang, H. Hu, et al., “Closed-Loop Theranostic Microgels for Immune Microenvironment Modulation and Microbiota Remodeling in Ulcerative Colitis,” Biomaterials 314 (2025): 122834.

[324] V. Kalidasan, X. Yang, Z. Xiong, et al., “Wirelessly Operated Bioelectronic Sutures for the Monitoring of Deep Surgical Wounds,” Nature Biomedical Engineering 5, no. 10 (2021): 1217–1227.

[325] R. W. Stidham, L. Cai, S. Cheng, et al., “Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis,” Gastroenterology 166, no. 1 (2024): 155–167.e2.

[326] B. Lo, B. Møller, C. Igel, et al., “Improving the Real-Time Classification of Disease Severity in Ulcerative Colitis: Artificial Intelligence as the Trigger for a Second Opinion,” American Journal of Gastroenterology (2025), https://doi.org/10.14309/ajg.0000000000003382.

[327] M. Iacucci, G. Santacroce, M. Yasuharu, and S. Ghosh, “Artificial Intelligence-Driven Personalized Medicine: Transforming Clinical Practice in Inflammatory Bowel Disease,” Gastroenterology (2025), https://doi.org/10.1053/j.gastro.2025.1003.1005.

[328] M. Iacucci, G. Santacroce, I. Zammarchi, et al., “Artificial Intelligence and Endo-Histo-Omics: New Dimensions of Precision Endoscopy and Histology in Inflammatory Bowel Disease,” Lancet Gastroenterology & Hepatology 9, no. 8 (2024): 758–772.

[329] T. Rozera, E. Pasolli, N. Segata, and G. Ianiro, “Machine Learning and Artificial Intelligence in the Multi-Omics Approach to Gut Microbiota,” Gastroenterology (2025), https://doi.org/10.1053/j.gastro.2025.1002.1035.

[330] X. Y. Liu, H. Tang, Q. Y. Zhou, et al., “Advancing the Precision Management of Inflammatory Bowel Disease in the Era of Omics Approaches and New Technology,” World Journal of Gastroenterology 29, no. 2 (2023): 272–285.

[331] D. Sahoo, L. Swanson, I. M. Sayed, et al., “Artificial Intelligence Guided Discovery of a Barrier-Protective Therapy in Inflammatory Bowel Disease,” Nature Communications 12, no. 1 (2021): 4246.

[332] S. Honap, V. Jairath, S. Danese, and L. Peyrin-Biroulet, “Navigating the Complexities of Drug Development for Inflammatory Bowel Disease,” Nature Reviews Drug Discovery 23, no. 7 (2024): 546–562.

[333] Y. Fu, X. Ding, M. Zhang, et al., “Intestinal Mucosal Barrier Repair and Immune Regulation With an AI-Developed Gut-Restricted Phd Inhibitor,” Nature Biotechnology (2024), https://doi.org/10.1038/s41587-41024-02503-w.

[334] N. S. Seyed Tabib, M. Madgwick, P. Sudhakar, B. Verstockt, T. Korcsmaros, and S. Vermeire, “Big Data in IBD: Big Progress for Clinical Practice,” Gut 69, no. 8 (2020): 1520–1532.

[335] S. Watanabe, S. Kobayashi, N. Ogasawara, et al., “Transplantation of Intestinal Organoids Into a Mouse Model of Colitis,” Nature Protocols 17, no. 3 (2022): 649–671.

[336] C. Tian, M. Yang, H. Xu, et al., “Stem Cell-Derived Intestinal Organoids: A Novel Modality for IBD,” Cell Death Discovery 9, no. 1 (2023): 255.

[337] A. Hammerhøj, D. Chakravarti, T. Sato, K. B. Jensen, and O. H. Nielsen, “Organoids as Regenerative Medicine for Inflammatory Bowel Disease,” iScience 27, no. 6 (2024): 110118.

[338] S. Rahman, M. Ghiboub, J. M. Donkers, et al., “The Progress of Intestinal Epithelial Models From Cell Lines to Gut-On-Chip,” International Journal of Molecular Sciences 22, no. 24 (2021): 13472.

[339] P. Banerjee and S. Senapati, “Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases,” Stem Cell Reviews and Reports 20, no. 6 (2024): 1441–1458.

[340] M. Lucafò, A. Muzzo, M. Marcuzzi, L. Giorio, G. Decorti, and G. Stocco, “Patient-Derived Organoids for Therapy Personalization in Inflammatory Bowel Diseases,” World Journal of Gastroenterology 28, no. 24 (2022): 2636–2653.

[341] L. Meran, L. Tullie, S. Eaton, P. De Coppi, and V. S. W. Li, “Bioengineering Human Intestinal Mucosal Grafts Using Patient-Derived Organoids, Fibroblasts and Scaffolds,” Nature Protocols 18, no. 1 (2023): 108–135.

[342] K. K. Jang, D. Hudesman, D. R. Jones, et al., “Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness,” Gastroenterology 167, no. 7 (2024): 1453–1456.e5.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Biomaterials and Applications published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).